{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-079880","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2025-08-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.773547+00:00","generated_at":"2026-05-17T11:58:01.766956+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"BioXcel Therapeutics files prospectus supplement for up to $80M ATM stock offering","bullets":["Filed prospectus supplement to sell up to $80M of common stock via ATM program with Canaccord Genuity.","ATM program established April 3, 2025; supplement filed August 18, 2025.","Honigman LLP issued validity opinion on shares; counsel's opinion filed as Exhibit 5.1.","Shares to be sold through any method deemed an 'at the market' offering under Rule 415(a)(4)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-079880","json":"https://secwatch.observer/filing/0001104659-25-079880.json","markdown":"https://secwatch.observer/filing/0001104659-25-079880.md","text":"https://secwatch.observer/filing/0001104659-25-079880.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925079880/0001104659-25-079880-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925079880/tm2523368d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T11:58:01.766956+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}